A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Enzyme Inhibitors
  • Molybdenum
  • Prostatic Neoplasms
  • Superoxide Dismutase

abstract

  • Low-dose ATN-224 (30 mg daily) may have biologic activity in men with biochemically-recurrent prostate cancer, as suggested by an improvement in PSA kinetics. However, the clinical significance of PSA kinetics changes in this patient population remains uncertain. The absence of a dose-response effect also reduces enthusiasm, and there are currently no plans to further develop this agent in prostate cancer.

publication date

  • July 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3227793

Digital Object Identifier (DOI)

  • 10.1016/j.urolonc.2011.04.009

PubMed ID

  • 21816640

Additional Document Info

start page

  • 581

end page

  • 8

volume

  • 31

number

  • 5